Flash Finance

Dr. Reddy's Laboratories LimitedDRREDDYCorporate

Healthcare Drug Manufacturers - Specialty & Generic Latest results: Jun 2026 15 quarters of data
Consolidated Standalone
₹1,233.00
MCap ₹102,707 Cr · P/E 31.4
Dr. Reddy's Laboratories Limited — Stock analysis & AI research Dr. Reddy's Laboratories Limited — Multibagger AI analysis Dr. Reddy's Laboratories Limited — Seasonality — best & worst months Dr. Reddy's Laboratories Limited — Technical indicators & charts Dr. Reddy's Laboratories Limited — Technical setup — score, trend, support & resistance Dr. Reddy's Laboratories Limited — Ascending Channel pattern forming Dr. Reddy's Laboratories Limited — Live exchange announcements
📋 High Interest Coverage Stocks📋 Mid Cap Stocks List 📈 MACD Bullish Crossover📈 Stocks Above Anchored VWAP 🏭 Pharma sector
AI-assisted data: figures and text on this page are extracted from public quarterly filings with AI assistance, checked automatically and overseen by our editorial team (human in the loop). They may still contain errors or omissions. Verify critical numbers against official company / SEBI / NSE / BSE filings before making any decision. Educational information only, not financial advice.
₹8,070 Cr
Sales · Jun 2026
-5.6% YoY
₹378 Cr
Operating Profit · Jun 2026
-78.3% YoY
4.7%
OPM % · Jun 2026
-77.1% YoY
₹435 Cr
Net Profit · Jun 2026
-69.2% YoY
₹5.32
EPS · Jun 2026
-68.8% YoY

📝 Dr. Reddy's Laboratories Limited — results explained

Quarter ended June 2026 (Q1 FY27)

Dr. Reddy's Laboratories Limited reported revenue of ₹8,070 crore for the quarter ended June 2026 (Q1 FY27), down 5.6% from ₹8,545 crore in the same quarter last year, and up 7.0% sequentially over the March 2026 quarter.

Net profit fell 69.2% year-on-year to ₹435 crore, from ₹1,410 crore. Earnings per share (EPS) came in at ₹5.32.

Operating profit stood at ₹378 crore — an operating margin (OPM) of 4.7%, compared with 20.5% in the year-ago quarter.

Full year and trailing twelve months

For the full year FY26, Dr. Reddy's Laboratories Limited posted revenue of ₹29,179 crore, a decline of 10.4% over FY25, with a net profit of ₹4,247 crore (down 25.8% year-on-year).

On a trailing-twelve-month (TTM) basis, revenue stands at ₹28,704 crore with a net profit of ₹3,273 crore.

Valuation snapshot

At the current price of ₹1,233.00, DRREDDY has a market capitalisation of ₹102,707 crore and a trailing P/E of about 31.4.

Within the Drug Manufacturers - Specialty & Generic industry, it is the 7th-largest of the 31 companies we track by market value.

Shareholding pattern

As of Jun 2026, promoters held 26.64%, foreign institutional investors (FIIs) 20.66%, domestic institutional investors (DIIs) 31.74%, public shareholders 20.76% of Dr. Reddy's Laboratories Limited.

📈 Share price & events

📊 Quarterly trend

₹ crore · OPM % on right axis

🎯 Key metrics

price-linked ratios use the latest close
Valuation
Market Cap ?
₹102,707 Cr
Current Price ?
₹1,233.0
P/E ?
31.38below ind
Industry P/E ?
35.00
P/B ?
2.71
P/S ?
3.58
P/FCF ?
51.25
Enterprise Value ?
₹110,441 Cr
EV/EBITDA ?
25.10
PEG ?
N/A
Earnings Yield ?
2.6%
Dividend Yield ?
0.65%
Profitability & Returns
Sales (TTM) ?
₹28,704 Cr
OPM ?
15.3%
Profit after tax (TTM) ?
₹3,273 Cr
EPS (TTM) ?
₹39.29
ROCE ?
14.0%
ROE ?
8.6%
ROA ?
5.6%
Growth
Sales — latest qtr ?
₹8,070 Cr
PAT — latest qtr ?
₹435 Cr
YoY qtr sales growth ?
-5.6%
YoY qtr profit growth ?
-69.2%
Sales growth (3y) ?
11%
Sales growth (5y) ?
12%
Profit growth (3y) ?
-3%
Profit growth (5y) ?
17%
Financial Health
Debt ?
₹7,734 Cr
Debt to Equity ?
0.20
Interest Coverage ?
11.6
Current Ratio ?
N/A
Ownership
Promoter holding ?
26.64%
Change in promoter holding ?
0.00%
Pledged percentage ?
N/A
Market
Return 3 months ?
1.8%
Return 6 months ?
-0.2%

🗓️ Quarterly results (15 quarters · ₹ Cr)

same fiscal quarter as Jun bestweakest per row · for costs (interest, NPAs) low is best
Metric Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 YoY % QoQ %
Sales 6,7706,2976,7386,8807,2157,1147,6738,0168,3598,5068,5458,8054,2837,5468,070 -5.6% +7.0%
Operating Profit 1,6421,2381,7641,7871,7271,8311,7922,0761,8721,7651,7481,7511,888382378 -78.3% -0.9%
Other Income 3412312016213819814931484306240174271480300 +24.8% -37.6%
Interest 42353735395960768266839141106126 +51.2% +18.4%
Depreciation 324316353376374368381397471455476505521557— — —
Profit Before Tax 1,6351,3261,8461,9131,8261,6051,8821,9171,8742,0051,9051,835104200553 -71.0% +176.3%
Net Profit 1,2479591,4021,4801,3791,3101,3921,3421,4041,5871,4101,4271,190221435 -69.2% +96.7%
EPS 75.0957.7484.4088.9682.8178.6683.5915.0516.9619.1317.0417.2614.502.655.32 -68.8% +100.8%
OPM % 24.3% 19.7% 26.2% 26.0% 23.9% 25.7% 23.4% 25.9% 22.4% 20.7% 20.5% 19.9% 44.1% 5.1% 4.7% -77.1% -7.8%

📆 Annual results (₹ Cr, FY = Apr–Mar)

Metric FY25 FY26 TTM YoY %
Sales ₹32,554 Cr ₹29,179 Cr ₹28,704 Cr -10.4%
Operating Profit ₹7,505 Cr ₹5,769 Cr ₹4,400 Cr -23.1%
OPM % 23.05% 19.77% 15.33% -14.2%
NPM % 17.59% 14.56% 11.40% -17.2%
Other Income ₹854 Cr ₹1,166 Cr ₹1,225 Cr +36.5%
Depreciation ₹1,704 Cr ₹2,059 Cr ₹1,583 Cr +20.8%
Interest ₹283 Cr ₹321 Cr ₹364 Cr +13.4%
EBIT ₹5,801 Cr ₹3,710 Cr ₹2,817 Cr -36.1%
PBT ₹7,678 Cr ₹4,044 Cr ₹2,692 Cr -47.3%
Tax — ₹408 Cr ₹526 Cr —
Net Profit ₹5,725 Cr ₹4,247 Cr ₹3,273 Cr -25.8%
EPS ₹134.73 ₹51.45 ₹39.73 -61.8%
Material Cost ₹3,780 Cr ₹7,674 Cr ₹8,308 Cr +103.0%
Employee Cost — — — —
Extraordinary Items — — — —

🏛️ Balance Sheet (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Equity Capital 83838384 +1.2%
Reserves 23,20328,17133,46637,808 +13.0%
Borrowings 1,3472,0024,6777,734 +65.4%
Other Liabilities 7,5768,5239,79712,498 +27.6%
Total Liabilities 32,20938,78048,02358,123 +21.0%
Fixed Assets 9,21910,42618,22622,063 +21.1%
CWIP 1,0301,4192,4661,460 -40.8%
Investments 4,9864,9304,0515,285 +30.5%
Other Assets 16,97422,00423,28029,315 +25.9%
Total Assets 32,20938,78048,02358,123 +21.0%

💧 Cash Flow (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Cash from Operating Activity 5,8884,5434,6435,674 +22.2%
Cash from Investing Activity -4,109-4,034-5,785-6,549 -13.2%
Cash from Financing Activity -2,686-3761,891829 -56.2%
Net Cash Flow -907133749-47 -106.3%
Free Cash Flow 4,0091,9081,3272,004 +51.0%
CFO/OP 108%83%78%109% +39.7%

➗ Ratios (latest 4 periods)

Metric Mar 2023Mar 2024Mar 2025Mar 2026 % Chg
Debtor Days 107105101110 +8.9%
Inventory Days 232283260228 -12.3%
Days Payable 1081169791 -6.2%
Cash Conversion Cycle 231271264247 -6.4%
Working Capital Days 8411869109 +58.0%
ROCE % 27%27%23%14% -39.1%

👥 Shareholding (latest 5 periods)

Metric Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026 % Chg
Promoters 26.64%26.64%26.64%26.63%26.64% +0.0%
FIIs 25.33%24.69%22.34%21.14%20.66% -2.3%
DIIs 26.73%27.99%30.44%30.72%31.74% +3.3%
Public 21.04%20.45%20.33%21.27%20.76% -2.4%
Others 0.26%0.25%0.25%0.24%— —
No. of Shareholders 4,51,9294,49,2164,55,2434,49,6654,46,086 -0.8%

⚖️ Peer comparison

Industry: Drug Manufacturers - Specialty & Generic · top 25 of 31 companies · full page →
# Company CMP MCap (Cr) P/E Sales TTM NP TTM OPM% NPM% Sales YoY% NP YoY% Qtr Rev Δ% Qtr NP Δ%
1 SUNPHARMA Sun Pharmaceutical ₹1,840.00 441,478 36.5 59,911 12,104 29.8% 20.2% 11.2% 5.1% 10.5% 27.0%
2 DIVISLAB Divi's Laboratories ₹9,235.00 245,160 83.8 11,230 2,925 35.3% 26.0% 12.8% 16.7% 27.8% 65.5%
3 TORNTPHARM Torrent Pharmaceuticals ₹4,931.00 187,559 87.1 15,723 2,156 33.0% 13.7% 21.4% 11.9% 54.8% 3.3%
4 ZYDUSLIFE Zydus Lifesciences ₹1,162.20 115,930 23.2 27,148 5,070 31.2% 18.7% 16.8% 12.0% 16.2% 14.5%
5 CIPLA Cipla ₹1,366.00 110,353 32.7 28,324 3,356 18.7% 11.8% 2.2% -26.7% 2.3% -39.2%
6 LAURUSLABS Laurus Labs ₹1,969.00 106,387 97.2 7,270 1,090 28.0% 15.0% 22.7% 147.9% 29.1% 123.9%
7 DRREDDY Dr. Reddy's ₹1,165.50 97,085 29.3 28,704 3,273 15.3% 11.4% -10.4% -25.8% -5.6% -69.2%
8 AUROPHARMA Aurobindo Pharma ₹1,679.80 96,652 26.2 34,935 3,711 20.3% 10.6% 6.1% 0.6% 16.3% 25.2%
9 LUPIN Lupin ₹2,095.00 95,797 17.9 27,958 5,356 31.5% 19.2% 23.1% 62.0% 31.9% 87.8%
10 MANKIND Mankind Pharma ₹2,280.00 94,174 46.1 14,738 2,067 26.0% 14.0% 16.3% -3.7% 12.9% 29.1%
11 GLENMARK Glenmark Pharmaceuticals ₹2,419.20 68,276 38.0 17,737 1,797 27.0% 10.1% -61.2% -67.4% 23.1% 927.9%
12 ALKEM Alkem Laboratories ₹5,243.50 62,694 29.1 15,081 2,187 20.1% 14.5% 13.5% 7.6% 10.9% -21.6%
13 ABBOTINDIA Abbott India ₹25,860.00 54,951 34.0 7,005 1,615 28.1% 23.1% 8.1% 9.7% 4.4% 17.2%
14 IPCALAB Ipca Laboratories ₹1,964.20 49,833 38.0 10,125 1,379 22.0% 13.6% 7.9% 55.0% 20.8% 82.2%
15 GLAND Gland Pharma ₹2,935.90 48,433 47.1 6,431 1,028 25.3% 16.0% -64.7% -48.4% 22.3% 96.7%
16 AJANTPHARM Ajanta Pharma ₹3,398.90 42,472 37.4 5,777 1,135 25.4% 19.7% 17.3% 14.8% 24.8% 30.9%
17 JBCHEPHARM J. B. ₹2,416.10 38,793 53.4 4,148 709 26.7% 17.1% 5.9% 7.5% -4.8% -30.7%
18 EMCURE EMCURE PHARMACEUTICALS ₹1,975.10 37,470 37.0 9,684 1,019 20.4% 10.5% 16.6% 33.1% 22.8% 36.0%
19 WOCKPHARMA Wockhardt ₹2,021.50 32,848 92.5 3,133 353 19.9% 11.3% -2.3% 342.1% 25.9% 199.1%
20 NEULANDLAB Neuland Laboratories ₹23,455.00 30,093 82.7 2,023 365 28.4% 18.0% 37.0% 40.2% 136.3% 666.0%
21 PPLPHARMA Piramal Pharma ₹211.50 28,024 113.5 9,206 247 11.0% 2.7% -3.1% -37.9% 17.4% -161.3%
22 GRANULES Granules India ₹885.60 21,945 32.8 5,633 663 22.7% 11.8% 19.7% 18.8% 22.0% 59.3%
23 CAPLIPOINT Caplin Point ₹2,752.60 20,923 31.4 2,287 678 34.8% 29.7% 12.9% 20.2% 19.6% 18.8%
24 ERIS Eris Lifesciences ₹1,358.00 18,820 29.0 3,230 666 35.2% 20.6% 8.2% 72.6% 13.0% 14.6%
25 ASTRAZEN AstraZeneca Pharma ₹6,755.00 16,888 99.6 2,432 170 9.4% 7.0% 32.7% 62.1% 29.7% -32.1%
❓ Frequently asked questions
What was Dr. Reddy's Laboratories Limited's revenue in Q1 FY27?
Dr. Reddy's Laboratories Limited reported revenue of ₹8,070 crore for the quarter ended June 2026 (Q1 FY27), down 5.6% from ₹8,545 crore in the same quarter last year, and up 7.0% sequentially over the March 2026 quarter.
What was Dr. Reddy's Laboratories Limited's net profit in Q1 FY27?
Net profit fell 69.2% year-on-year to ₹435 crore, from ₹1,410 crore. Earnings per share (EPS) came in at ₹5.32.
What is DRREDDY's market capitalisation and P/E ratio?
At the current price of ₹1,233.00, DRREDDY has a market capitalisation of ₹102,707 crore and a trailing P/E of about 31.4.
Who owns Dr. Reddy's Laboratories Limited? (shareholding pattern)
As of Jun 2026, promoters held 26.64%, foreign institutional investors (FIIs) 20.66%, domestic institutional investors (DIIs) 31.74%, public shareholders 20.76% of Dr. Reddy's Laboratories Limited.
TTM ends 2026-06-30. Amounts are ₹ crore unless stated otherwise. Figures are extracted by AI from public quarterly filings; gaps are filled from public market data. Live price refreshed about twice a day from exchange data. Educational information only — not financial advice.
⚠️ How this site is made: Market data pages are computed automatically from NSE/BSE publications and company filings; news articles and announcement analyses are written with AI assistance, with a human in the loop: our editors review what the AI produces. Both can contain errors. Verify with the original sources before any investment decision. Not investment advice; Flash Finance is not SEBI-registered. How we use AI